As a recent “demon stock”, Longjin Pharmaceutical (002750) has earned enough market attention. The stock price has risen by more than 200% in the past month, and it closed at the daily limit on January 12. With the stock price rising one after another, the major shareholders of Longjin Pharmaceutical couldn’t sit still. On the evening of January 12, Longjin Pharmaceutical announced that the company’s shareholder Lixing Industry Co., Ltd. (hereinafter referred to as “Lixing Industry”) plans to reduce its holdings of the company’s shares by no more than 24.03 million shares through centralized bidding, block transactions or other legal methods. , that is, not more than 6% of the company’s total share capital. After calculation, the market value of Lixing Industrial’s proposed reduction of shares exceeds 500 million yuan. It is understood that Lixing Industry is the second largest shareholder of Longjin Pharmaceutical, and the company’s controlling shareholder Kunming Qunxing Investment Co., Ltd. (hereinafter referred to as “Qunxing Investment”) and the actual controller Fan Xian’e just disclosed the reduction plan on January 7 .
Lixing Industrial sells and reduces its holdings after the stock price limit
On January 12, after Longjin Pharmaceutical achieved a daily limit, the shareholder Lixing Industrial planned to cash out at a high level.
On the evening of January 12, Longjin Pharmaceutical announced that its shareholder Lixing Industrial plans to reduce its holdings of the company’s shares by no more than 24.03 million shares through centralized bidding, block transactions or other legal means, that is, no more than 6% of the company’s total share capital. Among them, the reduction of no more than 8.01 million shares (accounting for 2% of the company’s total share capital) through centralized bidding will be carried out within 6 months after 15 trading days from the date of this announcement, and within any consecutive 90 natural days. The reduction of shareholding shall not exceed 1% of the company’s total share capital; the reduction of shareholding by block trading shall not exceed 16.02 million shares (accounting for 4% of the company’s total share capital), which will be 6 months after 3 trading days from the date of this announcement. within 90 consecutive natural days, and the reduction of shares held by the company shall not exceed 2% of the company’s total share capital.
The announcement shows that Lixing Industry holds 80.5823 million shares of Longjin Pharmaceutical (accounting for 20.12% of the company’s total share capital) and is the company’s second largest shareholder. Regarding the reason for this reduction, Longjin Pharmaceutical stated that it was the shareholders’ own business capital needs.
Behind Lixing Industrial’s plan to sell and reduce its holdings, Longjin Pharmaceutical’s stock price has risen sharply recently. According to the statistics of Oriental Fortune, from December 15, 2021 to January 12, 2022, in less than one month, Longjin Pharmaceutical’s stock price range has increased by as much as 203.74%, while the broader market fell by 4.73% during the same period.
In addition, on January 12, Longjin Pharmaceutical also closed at the daily limit, and its share price hit a new high since 2020. The trading market shows that on January 12, Longjin Pharmaceutical opened 0.85% higher, and the opening price was 20.08 yuan per share. After the opening, the company’s stock price continued to rise, and finally touched the upper limit. Although the intraday limit was broken several times, However, in the end, Longjin Pharmaceutical still closed at the daily limit, reporting a daily limit of 21.9 yuan per share, up 9.99%, with a total market value of 8.771 billion yuan, the day’s turnover was 1.151 billion yuan, and the turnover rate was 13.54%. If calculated roughly according to the closing price on January 12, Lixing Industrial can cash out about 526 million yuan this time.
In response to company-related issues, a reporter from Beijing Business Daily called the Office of the Secretary of the Board of Directors of Longjin Pharmaceutical for an interview, but no one answered the phone.
Controlling shareholders and actual controllers can cash out about 280 million yuan
A reporter from Beijing Business Daily noticed that with the stock price soaring, Longjin Pharmaceutical’s controlling shareholder Qunxing Investment and actual controller Fan Xian’e also disclosed a plan to reduce its holdings a few days ago. According to a rough calculation of the closing price on January 12, a total of about 280 million yuan can be cashed out.
Looking back at the previous announcement of Longjin Pharmaceutical, on January 7, Longjin Pharmaceutical stated that Qunxing Investment plans to reduce its holdings of the company’s shares by no more than 4.005 million shares (accounting for the capital) from January 28 to July 27, 2022. 1% of the company’s total share capital), the company’s shares will be reduced by no more than 8.01 million shares (accounting for 2% of the company’s total share capital) through centralized bidding, and the total reduction will not exceed 12.015 million shares (accounting for 3% of the company’s total share capital). The actual controller of the company, Fan Xianye, plans to reduce its holdings of shares acquired through centralized bidding transactions by no more than 775,400 shares, accounting for 0.19% of the company’s total share capital.
According to the announcement, Qunxing Investment holds about 166 million shares of Longjin Pharmaceutical, accounting for about 41.38% of the company’s total share capital, and Fan Xianye holds 3.1017 million shares of the company, with a shareholding ratio of 0.77%. The reason for the planned reduction of the two is due to business operations and shareholders’ capital needs.
In response to the successive reductions and cash-outs by major shareholders, investors discussed heatedly in the Longjin Pharmaceutical Stock Bar. Some investors said, “If you exceed the previous high, you will know that you don’t talk about martial arts.” “The last time you reduced your holdings by 3%, what about 6% this time?” In the opinion of investment and financing expert Xu Xiaoheng, after the stock price of listed companies has risen sharply, although the major shareholders’ plan to sell and reduce their holdings will not affect the company’s operations, it may affect investors’ investment sentiment.
According to the data, Longjin Pharmaceutical is mainly engaged in the research and development, production and sales of modern Chinese patent medicines and characteristic chemical generic medicines. Sex medicine wholesale and other businesses.
Financial data shows that in the first three quarters of 2021, Longjin Pharmaceutical achieved an operating income of about 594 million yuan, a year-on-year increase of 261.23%; the corresponding attributable net profit achieved was about 6.573 million yuan, a year-on-year increase of 187.68%.
Beijing Business Daily reporter Dong Liang Ding NingReturn to Sohu, see more
Editor:
Disclaimer: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.
.